Pietrantonio Filippo, Biondani Pamela, Verzoni Elena, Procopio Giuseppe
Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tumori. 2012 Mar-Apr;98(2):264-6. doi: 10.1177/030089161209800214.
The management of advanced genitourinary tumors is rapidly evolving thanks to the clinical availability of several targeted drugs with different mechanisms of action. Among clinicians, in-depth knowledge of all the aspects of the disease, together with the capacity to interpret and accurately correlate clinical data and imaging findings, are strongly needed. Moreover, the optimization of treatment sequences might lead to better disease control with respect to prognostic categories, radiological monitoring and newer biomarkers. Among the genitourinary tumors, only few data are available on bladder, testicular and penile cancers. Our report is supported by scientific and clinical experience in renal cell carcinoma and prostate cancer.
由于多种作用机制不同的靶向药物已临床可用，晚期泌尿生殖系统肿瘤的治疗正在迅速发展。临床医生亟需深入了解该疾病的各个方面，以及解读临床数据和影像结果并准确关联二者的能力。此外，优化治疗顺序可能会在预后分类、放射学监测和新型生物标志物方面带来更好的疾病控制效果。在泌尿生殖系统肿瘤中，关于膀胱癌、睾丸癌和阴茎癌的可用数据较少。我们的报告得到了肾细胞癌和前列腺癌的科学及临床经验的支持。
